proxyvotesnow.com

Home › Companies › 4D Molecular Therapeutics, Inc. › 2024-2025

4D Molecular Therapeutics, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and 4D Molecular Therapeutics, Inc.’s Form 8-K, filed 2025-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 145Asset managers
  • 1,006Fund votes
  • 2025-06-17Meeting date

Proxy season: 2024-2025 2025-2026

Explore 4D Molecular Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by 4D Molecular Therapeutics, Inc.

These tallies are 4D Molecular Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

4D Molecular Therapeutics, Inc. — official shareholder meeting results, meeting held 2025-06-17
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Jacob Chacko, M.D., MBA 28,579,453---- 3,691,9626,199,121 Majority: yes
Elect Director: Susannah Gray, MBA 31,923,027---- 348,3886,199,121 Majority: yes
Elect Director: Charles P. Theuer, M.D., Ph.D. 27,285,806---- 4,985,6096,199,121 Majority: yes
Proposal 3. The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement. 31,841,967394,00235,446 --6,199,121 Majority: yes

Source: 4D Molecular Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-06-20 — read the filing on EDGAR.

How asset managers voted at the 4D Molecular Therapeutics, Inc. 2024-2025 meeting

Each item below shows how the 145 asset managers that disclosed a 4D Molecular Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of 4D Molecular Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 31,841,967AGAINST: 394,002

4D Molecular Therapeutics, Inc.’s own tally for this item (“Proposal 3. The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”): 31,841,967 for, 394,002 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,778,127 outstanding shares: 64% for, 0.8% against (65% of the company cast a for/against vote).

The 144 asset managers below cast 99.6% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%
FOR: 98.9%AGAINST: 0.3%UNKNOWN: 0.8%NOT VOTED: 0.0%
Largest asset managers voting on “Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("s” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL4,585,9830 00For
RA CAPITAL MANAGEMENT, L.P.4,399,9450 00For
BlackRock3,977,8710 00For
Federated Hermes3,140,2900 00For
Vanguard2,769,3650 00For
Goldman Sachs2,149,6970 00For
Novo Holdings A/S2,000,0000 00For
Janus Henderson1,624,3910 00For
Two Sigma881,8310 00For
State Street845,3110 00For
JANUS INVESTMENT FUND844,3780 00For
MARSHALL WACE, LLP605,3420 00For
Charles Schwab569,7200 00For
ArrowMark Colorado Holdings LLC442,0720 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND412,0000 00For
Northern Trust342,7880 00For
ARMISTICE CAPITAL, LLC300,0000 00For
JPMorgan271,4070 00For
Decheng Capital LLC00 00Unknown
Wellington180,0780 00For
MELLON INVESTMENTS Corp175,5610 00For
Invesco155,5860 00For
Nuveen150,3140 00For
Redmile Group, LLC141,1780 00For
Equitable138,0930 00For

Showing the 25 largest of 144 asset managers. See all 144 in the interactive database.

2. Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99% fund support · no official result

1 YEAR 44%ONE YEAR 42%1-YR 14%

The 140 asset managers below cast 99% of the shares they voted on this item FOR (21,162 for, 303 against).

FOR: 21,162 (0.1%)AGAINST: 303 (0.0%)1 YEAR: 14,325,815 (43.9%)ONE YEAR: 13,632,793 (41.8%)1-YR: 4,585,983 (14.1%)THREE YEARS: 42,118 (0.1%)3 YEARS: 2,106 (0.0%)1-YEAR: 401 (0.0%)NOT VOTED: 96 (0.0%)
Largest asset managers voting on “Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL00 001-Yr
RA CAPITAL MANAGEMENT, L.P.00 00One Year
BlackRock00 001 Year
Federated Hermes00 001 Year
Vanguard00 00One Year
Goldman Sachs00 001 Year
Novo Holdings A/S00 001 Year
Janus Henderson00 00One Year
Two Sigma00 00One Year
State Street00 00One Year
JANUS INVESTMENT FUND00 00One Year
MARSHALL WACE, LLP00 001 Year
Charles Schwab00 001 Year
ArrowMark Colorado Holdings LLC00 001 Year
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND00 00One Year
Northern Trust00 001 Year
ARMISTICE CAPITAL, LLC00 001 Year
Wellington00 001 Year
MELLON INVESTMENTS Corp00 00One Year
Invesco00 00One Year
Nuveen00 00One Year
Redmile Group, LLC00 001 Year
Equitable00 00One Year
Citadel00 00One Year
MERIDIAN FUND INC00 001 Year

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

3. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Charles Theuer, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%
FOR: 27,285,806WITHHELD: 4,985,609

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles P. Theuer, M.D., Ph.D.”): 27,285,806 for, 4,985,609 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,778,127 outstanding shares: 54.8% for, 10% withheld (65% of the company cast a for/withheld vote).

The 44 asset managers below cast 100% of the shares they voted on this item FOR (8,401,540 for, 0 against).

FOR 96%
FOR: 8,401,540 (96.1%)ABSTAIN: 343,583 (3.9%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 55,8700For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4020 130For
American Century00 44,9100Abstain
Invesco00 38,7060Abstain
Lincoln Financial31,7000 4,8160For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust00 28,3110Abstain
Global X26,6800 00For
Northern Trust00 26,0960Abstain
AIG/SunAmerica00 23,0010Abstain
Brighthouse00 22,6990Abstain
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock00 18,7190Abstain
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I00 16,3500Abstain
Voya00 14,5000Abstain

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

4. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jacob Chacko, M.D., MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 28,579,453WITHHELD: 3,691,962

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Jacob Chacko, M.D., MBA”): 28,579,453 for, 3,691,962 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,778,127 outstanding shares: 57% for, 7% withheld (65% of the company cast a for/withheld vote).

The 44 asset managers below cast 100% of the shares they voted on this item FOR (8,466,342 for, 0 against).

FOR 97%
FOR: 8,466,342 (96.8%)ABSTAIN: 278,781 (3.2%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 55,8700For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4020 130For
American Century00 44,9100Abstain
Invesco38,7060 00For
Lincoln Financial31,7000 4,8160For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust00 28,3110Abstain
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica00 23,0010Abstain
Brighthouse00 22,6990Abstain
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock00 18,7190Abstain
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I00 16,3500Abstain
Voya00 14,5000Abstain

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

5. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Susannah Gray, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 31,923,027WITHHELD: 348,388

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Susannah Gray, MBA”): 31,923,027 for, 348,388 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 49,778,127 outstanding shares: 64% for, 0.7% withheld (65% of the company cast a for/withheld vote).

The 44 asset managers below cast 100% of the shares they voted on this item FOR (8,673,884 for, 0 against).

FOR 99.1%
FOR: 8,673,884 (99.2%)ABSTAIN: 71,239 (0.8%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 55,8700For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4150 00For
American Century44,9100 00For
Invesco38,7060 00For
Lincoln Financial31,7000 4,8160For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust28,3110 00For
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica23,0010 00For
Brighthouse22,6990 00For
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock18,7190 00For
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I16,3500 00For
Voya14,5000 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

6. Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 99.9% of the shares they voted on this item FOR (8,743,871 for, 1,252 against).

FOR: 8,743,871 (100.0%)AGAINST: 1,252 (0.0%)
Largest asset managers voting on “Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseC” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable138,0930 00For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4141 00For
American Century44,9100 00For
Invesco38,7060 00For
Lincoln Financial36,5160 00For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust28,3110 00For
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica23,0010 00For
Brighthouse22,6990 00For
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock18,7190 00For
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I16,3500 00For
Voya14,5000 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Largest 4D Molecular Therapeutics, Inc. shareholders voting in 2024-2025

Ranked by the number of 4D Molecular Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 49,778,127 shares outstanding at the time of that meeting.

Top 4D Molecular Therapeutics, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1BVF INC/IL 9.21%
2RA CAPITAL MANAGEMENT, L.P. 8.84%
3BlackRock 7.99%
4Federated Hermes 6.31%
5Vanguard 5.56%
6Goldman Sachs 4.32%
7Novo Holdings A/S 4.02%
8Janus Henderson 3.26%
9Two Sigma 1.77%
10State Street 1.70%

Reported 4D Molecular Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

4D Molecular Therapeutics, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
BVF PARTNERS L P/IL 10.74% 13G
JANUS HENDERSON GROUP PLC 10.54% 13G
RA Capital Management, L.P. 9.17% DEF14A
BlackRock 9.13% 13F
Goldman Sachs 8.37% 13F
Novo Holdings A/S 7.33% 13G
Vanguard Group 5.54% 13F
Biotechnology Value Fund, L.P. 5.37% DEF14A
Morgan Stanley 3.57% 13F
David Kirn, M.D. 3.33% DEF14A

Percentages above are of 49,778,127 shares outstanding, as reported by 4D Molecular Therapeutics, Inc. on its Form 10-K dated 2024-02-23 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D Molecular Therapeutics, Inc.’s 10-K dated 2024-02-23. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At 4D Molecular Therapeutics, Inc.'s shareholder meeting held 2025-06-17, in the 2024-2025 proxy season, 145 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,006 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory, non-binding basis, of the compensation of the Company's named… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 4D Molecular Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-20.

4D Molecular Therapeutics, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.